Novacyt S.A. Update on CE Mark Approved coronavirus test (1076D)
15 February 2020 - 2:20AM
UK Regulatory
TIDMNCYT
RNS Number : 1076D
Novacyt S.A.
14 February 2020
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Update on CE Mark Approved coronavirus test
Paris, France and Camberley, UK - 14 February 2020 - Novacyt (
EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in
clinical diagnostics, is pleased to announce that, further to its
announcement on 7 February 2020, its subsidiary, Primerdesign
Limited, is on schedule to launch a CE-Mark approved nCoV test in
the week commencing 17 February 2020. The Primerdesign website has
commenced taking orders for the CE-marked test ahead of the planned
launch next week.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Victoria Foster Mitchell/Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
About 2019-nCoV
Researchers at the Chinese Centre for Disease Control and
Prevention and their collaborators have sequenced the 2019 novel
coronavirus (2019-nCoV) pathogen from patient samples and have
found it to be genetically distinct from the severe acute
respiratory syndrome (SARS) virus that caused an epidemic in 2002
and 2003, as well as from the Middle East respiratory syndrome
(MERS) virus that was detected in 2012.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEZLFFBLLFBBZ
(END) Dow Jones Newswires
February 14, 2020 10:20 ET (15:20 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2024 to Jun 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Jun 2023 to Jun 2024